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BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for patients with acute myeloid leukemia
(AML). However, post-HCT relapse and regimen-related toxicity remain significant barriers to long-term survival. In recent years, new
conditioning regimens have been explored to improve transplantation outcomes in patients with AML. Treosulfan combines a potent
immunosuppressive and antileukemic effect with a low toxicity profile. METHODS: To investigate the role of treosulfan-based condi-
tioning, the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party performed a registry analysis of
520 adult patients with AML who received treosulfan-based conditioning and underwent HCT between 2000 and 2012, including 225
patients in first complete remission, 107 in second or later complete remission, and 188 with active/advanced disease 188 (88 with pri-
mary refractory disease). The median patient age was 57 years (range, 20-73 years). Donors were human leukocyte antigen-identical
siblings (n 5 187), unrelated donors (n 5 235), or mismatched related donors (n 5 98). Conditioning regimens included treosulfan (42
g/m2 [n 5 396], 36 g/m2 [n 5 109], or 30 g/ m2 [n 5 15]) with fludarabine or alkylating agents followed by infusion of hematopoietic
stem cells (bone marrow, n 5 52; peripheral blood, n 5 468). RESULTS: At a median follow-up of 61 months, the 5-year overall surviv-
al, leukemia-free survival, relapse incidence, and nonrelapse mortality rates were 38%, 33%, 42%, and 25%, respectively. The incidence
of grade II-IV acute and chronic graft-versus-host disease was 24% (grade III-V, 11%) and 38%, respectively. Only 11 patients (2%) de-
veloped veno-occlusive disease, with two deaths (0.4%) from veno-occlusive disease. CONCLUSIONS: Treosulfan-based conditioning
regimens provide an acceptable long-term survival with favorable nonrelapse mortality and a very low risk of veno-occlusive disease.
Further studies are needed to optimize the treosulfan-based conditioning regimen for patients with AML. Cancer 2017;123:2671-9.
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INTRODUCTION
Busulfan-based and total body irradiation (TBI)-based preparative regimens are widely regarded as standard conditioning
therapies for allogeneic hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML).1-5 A
significant challenge in the management of patients with high-risk AML is the relatively high transplantation-related mor-
tality associated with intensive HCT conditioning regimens. Thus, there is a need for conditioning regimens that reduce
the incidence of relapse without significantly increasing the risk of transplantation-related mortality.
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Traditionally, high-intensity conditioning regimens
have been standard practice for eradicating AML with
HCT. Busulfan is an effective immunosuppressive and
antileukemic agent. However, acute and late toxicities are
major challenges associated with this potentially curative
therapy.3,4,6-10 The common myeloablative conditioning
regimens used in AML include cyclophosphamide plus
TBI, cyclophosphamide plus busulfan, or fludarabine
plus busulfan. The use of high-dose busulfan and TBI are
associated with substantial hepatic toxicity, pulmonary
toxicity, neurotoxicity, and cardiotoxicity.1-4,6,8 Conse-
quently, it is important to identify less toxic conditioning
regimens that maintain the antileukemic, immunosup-
pressive, and myeloablative characteristics of conventional
conditioning therapies.
Treosulfan (a water-soluble, bifunctional alkylating
agent) has demonstrated efficacy as an antileukemic and
immunosuppressive agent.11 In contrast to busulfan, treo-
sulfan does not require enzymatic activation and thus
bypasses hepatic metabolism. Pharmacokinetic studies of
both single andmultiple intravenous infusions of treosulfan
have exhibited low interpatient and intrapatient variabili-
ty.11-13 In vitro studies have demonstrated strong proapop-
totic effects in human AML cells,11,14,15 and work from
murine xenograft models has revealed potent in vivo activi-
ty of treosulfan against acute and chronic leukemia, human
B-lymphoblast and T-lymphoblast cell lines, and various
solid tumors, myelomas, and lymphomas.11,14,16
Dose-limiting toxicities of treosulfan include bone
marrow suppression, which occurs at a dose of 10 g/m2,
suggesting that the drug may be effective for HCT condi-
tioning. In clinical trials with autologous HCT, the maxi-
mum tolerated cumulative dose of treosulfan could be
escalated from 10 to 47 g/m2 before mucositis, diarrhea,
dermatitis, or metabolic acidosis became dose-limiting.17
In those studies, no episodes of severe hepatotoxicity or
central nervous system toxicity were observed. Moreover,
treosulfan targets both committed and uncommitted he-
matopoietic stem cells and thus has profound antileuke-
mic and immunosuppressive properties.11,16,18 Although
data are limited, recent published studies have reported
encouraging results with acceptable nonhematologic tox-
icity.11,17,19-24 However, to date, no large trials have stud-
ied the value of treosulfan-based conditioning in HCT as
a potential alternative to the commonly used busulfan-
based or TBI-based regimens for patients with AML. In
this large, registry-based analysis, we report the safety and
efficacy of treosulfan-based conditioning for patients with
AML who undergo allogeneic HCT.
MATERIALS AND METHODS
Study Design and Data Collection
This is a retrospective, multicenter analysis with data provid-
ed by the Acute Leukemia Working Party (ALWP) of the
European Society for Blood and Marrow Transplantation
(EBMT) group registry, which is a voluntary working group
of more than 500 transplantations centers that are required
to report all consecutive stem cell transplantations and
follow-ups on an annual basis. Since 1990, registry patients
have provided informed consent authorizing the use of their
personal information for research purposes. The ALWP of
the EBMT group approved this study. The study protocol
was approved by the institutional review board at each site
and complied with country-specific regulatory requirements.
The study was conducted in accordance with theDeclaration
of Helsinki and good clinical practice guidelines.
Eligibility criteria for this analysis included adult
patients (age 18 years) with AML who received a
treosulfan-based conditioning regimen followed by a relat-
ed or unrelated donor (URD) bone marrow transplanta-
tion or granulocyte–colony-stimulating factor-mobilized
peripheral blood stem cells transplantation between the
years 2000 and 2012 (n5 520 patients; n5 19 transplan-
tation centers). Treosulfan was combined with different
chemotherapeutic agents, most frequently with fludarabine
(94%) or cyclophosphamide (3.5%). The most frequent
dose range for treosulfan was from 36 to 42 g/m2 (Table 1).
Standard dosages were used for the other chemotherapeu-
tic agents in the majority of patients (median dosages: cy-
clophosphamide, 120 mg/kg; interquartile range [IQR],
78-120 mg/kg; fludarabine, 150 mg/m2; IQR, 150-150
mg/m2; thiotepa, 10 mg/kg; IQR, 10-10 mg/kg; and mel-
phalan. 140 mg/m2; IQR, 140-140mg/m2).
The variables investigated included recipient and
donor characteristics (age, sex, cytomegalovirus serosta-
tus); disease features (including remission status, active/
advanced disease); transplantation-related factors, includ-
ing conditioning regimen, immunosuppression (in vivo
T-cell depletion vs none), stem cell source (bone marrow
or peripheral blood), graft-versus-host disease (GVHD)
prophylaxis; and outcome variables, including acute and
chronic GVHD, relapse, nonrelapse mortality (NRM),
leukemia-free survival (LFS), overall survival (OS), and
causes of death. The choice of conditioning and GVHD
prophylaxis depended on transplantation center protocols
and strategies for transplantation.
Statistical Analysis
The primary endpoints of this study were LFS and OS.
Secondary endpoints included disease relapse incidence
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(RI), NRM, engraftment, incidence and severity of acute
and chronic GVHD, and risk of veno-occlusive disease of
the liver (VOD).10 The starting point for time-to-event
analysis was “date of transplantation.” OS was defined as
the time to death from any cause, LFS was defined as sur-
vival without relapse or progression, and RI was defined
as the time to onset of leukemia recurrence. For OS, LFS,
and RI, patients were censored at the time of last follow-
up. NRM was the competing risk, and patients who sur-
vived in continuous complete remission (CR) were cen-
sored at last contact. NRM was defined as death without
relapse/progression (relapse was the competing risk).
Competing risks considered for GVHD were relapse or
death. Standard definitions were used to define remission
status.3,4,25 The groups were compared using the chi-
square method for qualitative variables, and the Mann-
Whitney test was applied for continuous parameters.
Univariate comparisons were done using the log-
rank test for OS and LFS and the Gray test for RI, NRM,
and GVHD cumulative incidence. Multivariate analyses
were performed using Cox proportional hazards model
for all endpoints. All factors known as potentially related
to the outcomes were included in the model with stepwise
selection. All tests were 2-sided. The Type I error rate was
fixed at .05 for determination of factors associated with
time-to-event outcomes. Statistical analyses were per-
formed using the software packages SPSS 22.0 (IBM
Corp., Armonk, NY) and R 3.2.3 (R Development Core
Team, Vienna, Austria).
RESULTS
Patient and Transplantation Characteristics
Five hundred twenty patients with AML (median age, 57
years; IQR, 47-63 years) who received a treosulfan-based
conditioning regimen followed by HCT from a related
donor (n 5 285) or an URD (n 5 235) between 2000
and 2012 were included in this analysis (patient character-
istics are summarized in Table 1). Patients received treo-
sulfan at a dose of 42 g/m2 (n5 396), 36 g/m2 (n5 109),
or 30 g/m2 (n 5 15) over 3 days. Four hundred eighty-
four patients (94%) received a treosulfan and fludarabine-
based conditioning regimen (Table 1). In total, 225
patients (43%) were in first CR (CR1), 107 (21%) were
in second CR or later (CR2), and 188 (36%) had ac-
tive/advanced disease (primary refractory, n 5 88) before
HCT (Table 1).
Engraftment
Twenty patients (4%) patients died before day 60 (18 of
whom died before day 30) without attaining engraftment.
The remaining 490 patients (96%) attained engraftment,
with a median day to an absolute neutrophil count
(ANC) 500/lL of 16 days (IQR, 13-20 days). The en-
graftment rates were 94% at day 30 for neutrophils and
93% at day 180 for platelets. One patient had graft
rejection.
TABLE 1. Patient, Disease, and Transplantation
Characteristics
Characteristic No. of Patients (%)
Patient characteristics, n 5 520
Recipient age at HCT: Median [IQR], y 57 [47-63]
Recipient sex
Man 266 (51)
Woman 254 (49)
Follow-up: Median [range], moa 61 [2-163]
Interval from diagnosis to HCT: Median [range], d 218 [60-2358]
Year of transplantation: Median [range], y 2009 [2000-2012]
Donor sex
Man 308 (60)
Woman 210 (40)
Unknown 2
Female donor to male recipient 105 (20)
Missing 2
Disease characteristics
Disease status at HCT
CR1 225 (43)
CR2 107 (21)
Active/advanced disease, n 5 188 188 (36)
Primary refractory 88
First refractory relapse 86
Second or later refractory relapse 14
Secondary AML 136 (26)
Cytogenetics
Good 34 (7)
Intermediate 234 (45)
Poor 74 (14)
NA/missing 42 (8)
KPS at HCT
<90% 143 (28)
Missing 8
Transplantation characteristics
Donor type
Related 285 (55)
Unrelated 235 (45)
CMV serology
Patient positive 391 (76)
Missing 4
Donor positive 271 (53)
Missing 8
Stem cell source
BM 52 (10)
PB 468 (90)
Conditioning regimen
Treosulfan and fludarabine 484 (94)
In vivo T-cell depletion 279 (52)
ATG 264
Campath 15
Abbreviations: AML, acute myeloid leukemia; ATG, antithymocyte globulin;
BM, bone marrow; CMV, cytomegalovirus; CR1, first complete remission;
CR2, second or later complete remission; HCT, allogeneic cell transplan-
tation; IQR, interquartile range; KPS, Karnofsky performance status; NA,
not applicable; PB, peripheral blood.
a Some percentages do not add up to 100% because of rounding.
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Acute GVHD
Acute GVHD (grade II-IV) was observed in 123 patients
(24%), and grade III and IV acute GVHD was observed
in 54 patients (11%). There were no significant differ-
ences in the frequency of acute GVHD in the treosulfan
dosing groups (grade II-IV: 18% of patients in the 36 g/m2
group vs 26% of those in the 42 g/m2 group [P 5 .11];
grade III-IV: 6% of patients in the 36 g/m2 group vs 12%
of those in the 42 g/m2 group [P5 .06]) (Table 2).
In multivariate analysis, the factor associated most
significantly with increased risk of grade II-IV acute
GVHD was active disease (hazard ratio [HR], 1.66; 95%
confidence interval [CI], 1.11-2.49; P 5 .015). In con-
trast, T-cell depletion was associated with a reduced risk
of acute GVHD (HR, 1.71; 95% CI, 1.17-2.50; P 5
.006) (Table 3).
Chronic GVHD
The 5-year cumulative incidence of chronic GVHD was
38% (95% CI, 34%-43%) (Table 4). Low-dose treosul-
fan was associated with a lower incidence of chronic
GVHD in univariate analysis (30%; 95% CI, 22%-39%)
in the group that received 36 g/m2 versus 41% (95% CI,
36%-46%) in the group that received 42 g/m2 (P5 .03).
In multivariate analysis, the risk factor most signifi-
cantly associated with chronic GVHD was belonging to
the poor cytogenetic risk group (HR, 1.52; 95% CI,
1.01-2.27; P 5 .044). Consistent with our findings in
acute GVHD, T-cell depletion reduced the risk of chron-
ic GVHD (HR, 0.70; 95% CI, 0.51-0.97; P 5 .03)
(Table 3).
NRM
The 5-year cumulative incidence of NRMwas 25% (95%
CI, 21%-29%) (Table 4). In univariate analysis, there was
TABLE 2. Engraftment and Graft-Versus-Host Disease Data
No. of Patients (%)a
Variable All Patients Treosulfan 36 g/m2 Treosulfan 42 g/m2
Engraftment
Yes 490 (96) 96 (91) 376 (96)
No 20 (4) 9 (9) 14 (4)
Unknown 10 4 6
Time to PMN cells 500/lL: Median [IQR], d 16 [13-20] 15 [12-16] 15 [12-18]
Acute GVHD: [95% CI], %
Grade II-IV 24 [21-28] 18 [1-26] 26 [21-30]
Grade III-IV 11 [8-14] 6 [2-11] 12 [9-15]
Unknown 10 4 6
Chronic GVHD: [95% CI], % 38 [34-43]b 30% [22-39]b 41% [36-46]b
Limited 89 17 71
Extensive 104 15 87
Unknown 3 1 2
Abbreviations: GVHD, graft-versus-host disease; IQR, interquartile range; MAC, myeloablative conditioning; PMN, polymorphonuclear cells; RIC, reduced-
intensity conditioning.
a Some percentages may not add up to 100% because of rounding.
b The 5-year cumulative incidence is indicated.
TABLE 3. Multivariate Analysis: Patients Who Re-
ceived Treosulfan >30 g/m2
Variable P HR [95% CI]
Relapse
Active disease (Ref, CR1) < .0001 3.34 [2.40-4.65]
Poor cytogenetic group .04 1.71 [1.19-2.45]
URD (Ref, MSD) .0001 0.49 [0.34-0.71]
Other relative (Ref, MSD) .019 0.56 [0.35-0.91]
In vivo T-cell depletion .023 1.54 [1.06-2.24]
NRM
Age at SCT (by 110 years) .006 1.29 [1.07-1.54]
Active disease (Ref, CR1) .001 2.12 [1.37-3.28]
KPS 90% .010 0.59 [0.40-0.88])
Acute GVHD
Active disease (Ref, CR1) .015 1.66 [1.11-2.49]a
Secondary AML .049 1.49 [1.00-2.21]a
In vivo T-cell depletion .006 1.71 [1.17-2.50]a
Chronic GVHD
Poor cytogenetic group .044 1.52 [1.01-2.27]
In vivo T-cell depletion .03 0.70 [0.51-0.97]
LFS
Active disease (Ref, CR1) < .0001 2.95 [2.27-3.83]
CR2 (Ref, CR1) .003 1.58 [1.16-2.15]
Poor cytogenetic group .003 1.55 [1.16-2.08]
URD (Ref, MSD) .037 0.74 (0.56-0.98]
OS
Active disease (Ref, CR1) < .0001 2.80 [2.16-3.62]
CR2 (Ref, CR1) .003 1.63 [1.19-2.25]
Poor cytogenetic group .0004 1.70 [1.27-2.29]
Abbreviations: CI, confidence interval; CR, complete remission; CR1, first
complete response; CR2, second complete remission; GVHD, graft-versus-
host disease; HCT, allogeneic hematopoietic cell transplantation; HR, hazard
ratio; KPS, Karnofsky performance status; LFS, leukemia-free survival; MSD,
matched sibling donor; NRM, nonrelapse mortality; OS, overall survival; Ref,
reference category; SCT, stem cell transplantation; URD, unrelated donor.
aOdds ratio [95% CI].
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no significant difference in the incidence of NRM among
patients who received 36 g/m2 versus 42 g/m2 of treosul-
fan (20% [95% CI, 2%-54%] vs 27% [95% CI, 3%-
60%]; P 5 .17) (Table 4). However, there was a signifi-
cantly higher incidence of NRM in patients who received
the higher dose of treosulfan and underwent transplanta-
tion in CR1 (9% [95% CI, 3%-19%] for 36 g/m2 vs 20%
[95% CI, 9%-33%] for 42 g/m2; P 5 .03) but not in
those with active/advanced disease at HCT (33% [95%
CI, 18%-49%] vs 32% [95% CI, 24%-40%]; P 5 .77)
(Table 4).
In multivariate analysis, the factors associated with
an increased risk of NRM were age at HCT (by 110
years: HR, 1.29; 95% CI, 1.07-1.54; P5 .0006) and dis-
ease status at transplantation (for active/advanced disease:
HR, 2.12; 95% CI, 1.37-3.28; P 5 .001). Conversely, a
Karnofsky performance status 90% was associated with
a decreased risk of NRM (HR, 0.59; 95% CI, 0.40-0.88;
P5 .01) (Table 3).
Relapse
The 5-year cumulative RI was 42% (95% CI, 37%-46%)
(Table 4). There was no significant association between
RI and treosulfan dose in univariate analysis (45% [95%
CI, 35%-54%] in the 36 g/m2 group vs 40% [95% CI,
35%-45%] in the 42 g/m2 group; P 5 .25). Analyzing
patients in CR1 (39% [95% CI, 24%-53%] vs 31%
[95% CI, 24%-38%], respectively; P 5 .22) and those
with active/advanced disease did not reveal a significant
difference in RI in the 2 treatment groups (54% [95% CI,
36%-69%] vs 55% [95% CI, 46%-63%], respectively;
P5 .90) (Table 4).
In multivariate analysis, the factors associated with
an increased risk of relapse included disease status at trans-
plantation (for active/advanced disease: HR, 3.34; 95%
CI, 2.40-4.65; P < .0001), poor cytogenetics (HR, 1.71;
95% CI, 1.19-2.45; P5 .004), and T-cell depletion (HR,
1.54; 95% CI, 1.06-2.24; P5 .023). Patients who under-
went HCT from a URD and a mismatched-related donor
experienced a significantly lower risk of relapse compared
with those who underwent HCT from a matched-related
donor (URD: HR, 0.49; 95% CI, 0.34-0.71; P 5 .0001;
mismatched-related donor: HR 0.56; 95% CI, 0.35-0.91;
P5 .019) (Table 3).
LFS
The 5-year LFS rate for the entire cohort was 33% (95%
CI, 28%-37%) (Table 4, Fig. 1). There was no significant
association between LFS and treosulfan dose in univariate
analysis (35% [95% CI, 26%-45%] in the 36 g/m2 group
vs 33% [95% CI, 28%-38%] in the 42 g/m2 group; P 5
.83). This difference remained nonsignificant when we
separately analyzed patients in CR1 (53% [95%CI, 38%-
68%] vs 50% [95% CI, 42%-57%]; P 5 .69) and those
who had active/advanced disease (12% [95% CI, 1.3%-
23%] vs 13% [95%CI, 7%-19%]; P5 .60).
In multivariate analysis, risk factors for inferior LFS
were disease status at transplantation (for active/advanced
disease: HR, 2.95; 95% CI, 2.27-3.83; P < .0001) and
poor cytogenetics (HR, 1.55; 95% CI, 1.16-2.08; P 5
.003). Patients who received URD allografts had
TABLE 4. Five-Year Outcome After a Treosulfan-Based Conditioning Regimen in Patients With Acute
Myeloid Leukemia
Outcome %, [95% CI]
Patient
Group
Relapse
Incidence
Nonrelapse
Mortality
Leukemia-Free
Survival
Overall
Survival
Acute GVHD
(Grade III-IV)
Chronic
GVHD
All patients 42 [37-46] 25 [21-29] 33 [28-37] 38 [33-42] 11 [8-14] 38 [34-43]
Treosulfan dose, g/m2
30 62 [29-83] 22 [2-55] 17 [0-37] 25 [2-48] 7 [0.4-27] 23 [5-50]
36 45 [35-54] 20 [2-54] 35 [26-45] 41 [31-51] 6 [2-11] 30 [22-39]
42 40 [35-45] 27 [3-60] 33 [28-38] 38 [32-43] 12 [9-16] 41 [36-46]
P (36 vs 42 g/m2) .25 .17 .83 .68 .06 .03
CR1
36 39 [24-53] 8.5 [3-19] 53 [38-68] 65 [51-79] 6 [2-16] 39 [25-53]
42 31 [24-38] 20 [9-33] 50 [42-57] 53 [45-61] 10 [6-15] 45 [37-52]
P .22 .03 .69 .28 .49 .46
Advanced disease
36 54 [36-69] 33 [18-49] 12 [1.3-23] 14 [1.3-26] 3 [0.2-13] 26 [12-43]
42 55 [46-63] 32 [24-40] 13 [7-19] 18 [12-25] 16 [10-22] 37 [29-45]
P .90 .77 .60 .97 .04 .18
Abbreviations: CI, confidence interval; CR1, first complete remission; GVHD, graft-versus-host disease.
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significantly higher LFS (HR, 0.74; 95%CI, 0.56-0.98; P
5 .037) (Table 3).
OS
The 5-year OS rate for the entire cohort was 38% (95%
CI, 33%-42%) (Table 4, Fig. 1). There was no significant
association between OS and treosulfan dose (41% [95%
CI, 31%-51%] in the 36 g/m2 group vs 38% [95% CI,
32%-43%] in the 42 g/m2 group; P 5 .68). This differ-
ence remained nonsignificant when we separately ana-
lyzed patients in CR1 (65% [95% CI, 51%-79%] vs 53%
[95% CI, 45%-61%]; P5 .28) and those with active/ad-
vanced disease (14% [95% CI, 1.3%-26%] vs 18% [95%
CI, 12%-25%]; P5 .97).
In multivariate analysis, the factors associated with
inferior OS were disease status at transplantation (for ac-
tive/advanced disease; HR 2.80; 95% CI, 2.16-3.62; P <
.0001) and poor-risk cytogenetics (HR, 1.70; 95% CI,
1.27-2.29; P5 .0004) (Table 3).
Causes of Death
In total, 324 patients died after a median follow-up of 61
months (IQR, 34-84 months). Major causes of deaths
were progression or recurrence of the original disease (n5
149; 48%) and infection (n5 82; 26%). Causes of deaths
are summarized in Table 5.
VOD
VOD occurred in eleven (2.2%) patients with two deaths
(0.4%). VOD was classified as mild (n5 4), moderate (n
5 2), and severe (n5 3). VOD classification was missing
in 2 patients (both remained).
Impact of Treosulfan Dose and Combination
With Other Agents on Transplantation Outcome
A higher treosulfan dose (42 vs 36 g/m2) was associated
with increased NRM for patients in CR1 in the univariate
analysis. In an adjusted multivariate analysis, there was no
impact of treosulfan dose on NRM. In addition, the treo-
sulfan dose had no impact on acute or chronic GVHD,
NRM, relapse, LFS, or OS.
Most patients received the combination of treosul-
fan and fludarabine, so we were unable to analyze the im-
pact of treosulfan in combination with other agents on
transplantation outcomes. There was no significant
Figure 1. The probabilities of (A) overall survival and (B) leukemia-free survival after a treosulfan-based conditioning regimen for
acute myeloid leukemia are illustrated. CR1 indicates first complete remission.
TABLE 5. Causes of Death
Cause of Death No. of Deaths (%)
Cardiac toxicity 3
Hemorrhage 5
VOD 2
Infection 82 (26)
IP 3
GVHD 43 (14)
Original disease 149 (48)
Second malignancy 7
Other transplantation-related causes 15
Other 4
Missing information 11
Total deaths 324
Abbreviations: GVHD, graft-versus-host disease; IP, interstitial pneumonitis;
VOD, veno-occlusive disease of the liver (sinusoidal obstructive syndrome).
Original Article
2676 Cancer July 15, 2017
interaction between treosulfan dose (36 or 42 g/m2) and
disease status at transplantation.
DISCUSSION
TBI-based or busulfan-based ablative conditioning regi-
mens are the most commonly used for patients with AML
who undergo HCT, despite significant acute and late tox-
icities.1-4,8,9,25-29 In recent years, new conditioning regi-
mens have been explored to improve transplantation
outcomes in AML. Treosulfan is a possible alternative to
be used in conditioning regimens that have strong immu-
nosuppressive and myelosuppressive effects in preclinical
models. Both in vitro studies and in vivo human mouse
models of treosulfan have demonstrated significant anti-
leukemic activity, comparable to the activity of other che-
motherapeutic agents.11,16,30 In addition, treosulfan has a
lower toxicity profile and the additional advantage of line-
ar pharmacokinetics that do not require the monitoring of
drug levels like busulfan.11,17,19,21,23,24,31
Hepatotoxicity in our study was low. We observed
VOD in only 2.2% of patients (with only 2 deaths related
to VOD), similar to earlier reports from studies of treosul-
fan.11,32-38 Other myeloablative regimens reportedly were
associated with higher VOD rates, especially with a com-
bination of busulfan plus cyclophosphamide or when
melphalan was added as a third drug.10,26,28 In addition,
the pulmonary toxicity profile of treosulfan-based regi-
mens was low. Three patients died because of interstitial
pneumonitis in our series (Table 5), and 1 patient devel-
oped pulmonary dysfunction with VOD (patient sur-
vived). Historically, the reported incidence of pulmonary
toxicity with TBI-based or busulfan-based regimens was
up to 14%with high mortality.27,39,40 This is noteworthy,
because more than one-third of patients in our series had
active/advanced disease, which is high risk for organ
toxicities.
A recent, retrospective EBMT study32 evaluated the
toxicity profile and outcomes of 71 children with acute
lymphoblastic leukemia who underwent HCT after a
treosulfan-based conditioning with results that were simi-
lar to ours. Those investigators reported a high engraft-
ment rate of 97%, comparable to the data presented here
and to earlier studies that used treosulfan with low
regimen-related toxicities.11,32-36,38,41 A very low inci-
dence of graft rejection (only 1 event) and GVHD also
was reported in a recent, large series of treosulfan-based,
haploidentical HCT.42 In that study, severe, acute
GVHD (grade III or IV) was observed in 14% of patients,
comparable to earlier treosulfan studies and our current
findings (11%).11,32,33,35
The long-term outcomes of this large treosulfan-
based series were 5-year OS and LFS rates of 38% and
33%, respectively. Outcomes correlated significantly with
disease status at transplantation, as expected, similar to
previous studies with TBI-based or busulfan-based condi-
tioning regimens. Patients in CR1 had significantly better
OS and LFS compared with patients in CR2 (Table 4).
A major cause of treatment failure was relapse in 31% of
patients at 1 year and in 36% of patients at 2 years. The
incidence of relapse was higher in patients beyond CR1
(Table 4), resulting in a 5-year OS rate of 55% for patients
who underwent transplantation in CR1, 37% for those
who underwent transplantation in CR2, and 18% for
those with active/advanced disease. These results are com-
parable to those reported from studies that used busulfan-
based or TBI-based ablative conditioning regimens.3,4
Our data indicate that treosulfan is an effective con-
ditioning regimen for HCT in patients who have AML in
CR at the time of HCT, with a lower toxicity profile com-
pared with that of conventional myeloablative condition-
ing regimens. This makes treosulfan-based regimens
potentially applicable to older patients and/or patients
with advanced disease. To our knowledge, this is the larg-
est registry study of treosulfan-based conditioning in an
AML cohort with data demonstrating comparable long-
term outcomes with a low risk of early organ toxicity and
acute GVHD compared with historic data using ablative
regimens in AML. These results, which must be con-
firmed in prospective studies, indicate that treosulfan may
represent a viable alternative to TBI-based or busulfan-
based conditioning regimens.
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